BNIP3 and neoplasm: As shown in Figure 4, the PINK1/Parkin activator enhances treatment sensitivity and reduces tumor growth and metastasis, while the BNIP3/NIX inhibitor promotes cell survival and drug resistance, facilitating tumor progression.